Apple, Samsung Bet on AI to Make Glucose Data Actionable
Your smartwatch may not measure blood sugar, but AI could explain what it means.
The dream of glancing at your wrist for a blood sugar reading remains out of reach. Despite years of research, Apple, Samsung, and other wearable makers have not delivered FDA-cleared, noninvasive glucose sensors—and the FDA warns consumers against relying on such claims. As a result, the near-term opportunity is no longer about a sensor breakthrough but about what happens after data is collected. Continuous glucose monitors (CGMs), already used by millions for diabetes, generate streams of data on meals, sleep, stress, and exercise. The next battleground is the AI layer that turns those raw curves into actionable, personalized guidance—without crossing into medical advice. Apple and Samsung have the platforms to compete: Apple Watch, Health app, and Apple Intelligence on one side; Galaxy Watch, Ring, and Galaxy AI on the other. Oura and Dexcom are already moving in this direction. The risk is that wellness nudges like “eat fewer carbs after 6 PM” could sound dangerously like clinical recommendations, requiring careful FDA boundaries. This race could redefine how consumer wearables deliver health insights.
- No current smartwatch offers FDA-cleared noninvasive blood glucose monitoring, and the FDA has warned against such claims.
- AI software that interprets CGM data—linking glucose spikes to meals, sleep, and stress—is becoming the primary differentiator for Apple, Samsung, Oura, and Dexcom.
- The shift from sensing to interpretation carries regulatory risks, as wellness advice may blur into medical guidance.
Why It Matters
Professionals managing metabolic health could soon get AI-driven, actionable insights from their wearable data.